Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari

Articles

stethoscope

Retrospective cohort study on absolute risks of diabetic ketoacidosis

Diabetes

Retrospective cohort study using patient records data from Canada and the UK between 2013 and 2018 compared the incidences of diabetic ketoacidosis in type 2 diabetes patients receiving SGLT2 (sodium glucose co-transporter 2) inhibitors vs. DPP4 (dipeptidyl peptidase 4) inhibitors.

 

Read More

Prescribing information for Invokana (canagliflozin)

Healthcare professional using a microscope

SGLT2 inhibitors superior vs. DPP4 inhibitors, findings from a meta-analysis

Diabetes

Researchers carried out a meta-analysis on 30 studies that compared the effects of SGLT2 (sodium glucose co-transporter 2) inhibitors vs. DPP4 (dipeptidyl peptidase 4) inhibitors in type 2 diabetes, and found superiority of SGLT2 inhibitors over DPP4 inhibitors across a broad spectrum of cardiovascular (CV) outcomes and metabolic risk factors.

Read More

Prescribing information for Invokana (canagliflozin)

nurse

Canagliflozin is estimated to delay time to dialysis by approximately 13 years, an analysis using CREDENCE trial data

Diabetes

On top of standard of care with ACE inhibitors or ARBs, the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial showed that canagliflozin slowed down renal function decline and delays progression to end-stage kidney disease compared to placebo in patients with type 2 diabetes and chronic kidney disease. When individuals reach end-stage kidney disease, dialysis is the most common therapy required, which represents poor disease prognosis and poor quality of life. What does this slowing down of renal function decline mean in terms of delaying time to dialysis for patients?

Read More

Prescribing information for Invokana (canagliflozin)

Stethoscope Medical instrument

The renoprotective effects of SGLT2 inhibitors first demonstrated in CREDENCE within a T2DM population have now been confirmed in DAPA-CKD, a trial that also included patients without T2DM

Diabetes

Patients with chronic kidney disease (CKD) have a high risk of adverse cardiovascular and renal outcomes. Sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown favourable effects on renal and cardiovascular outcomes in large clinical trials involving patients with type 2 diabetes (T2DM), although the majority of patients enrolled in those studies did not have CKD.

Read More

Prescribing information for Invokana (canagliflozin)

ESC update on SGLT2 inhibitors in heart failure: position paper from the Heart Failure Association

ESC update on SGLT2 inhibitors in heart failure: position paper from the Heart Failure Association

Diabetes

The European Society of Cardiology (ESC) recently published its updated 2021 guidelines for the diagnosis and treatment of acute and chronic heart failure (HF)1 , with contribution of the Heart Failure Association (HFA) of the ESC, who earlier issued an updated position paper2 on the recommendations for the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors in the prevention and treatment of heart failure.

Read More

Prescribing information for Invokana (canagliflozin)